2-phenylquinazolinones as dual-activity tankyrase-kinase inhibitors
Nkizinkiko, Yves; Desantis, Jenny; Koivunen, Jarkko; Haikarainen, Teemu; Murthy, Sudarshan; Sancineto, Luca; Massari, Serena; Ianni, Federica; Obaji, Ezeogo; Loza, Maria I.; Pihlajaniemi, Taina; Brea, Jose; Tabarrini, Oriana; Lehtiö, Lari (2018-01-26)
Nkizinkiko, Y., Desantis, J., Koivunen, J., Haikarainen, T., Murthy, S., Sancineto, L., Massari, S., Ianni, F., Obaji, E., Loza, M., Pihlajaniemi, T., Brea, J., Tabarrini, O., Lehtiö, L. (2018) 2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors. Scientific Reports, 8, 1680. doi:10.1038/s41598-018-19872-3
© The Author(s) 2018. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ .
https://creativecommons.org/licenses/by/4.0/
https://urn.fi/URN:NBN:fi-fe201803146023
Tiivistelmä
Abstract
Tankyrases (TNKSs) are enzymes specialized in catalyzing poly-ADP-ribosylation of target proteins. Several studies have validated TNKSs as anti-cancer drug targets due to their regulatory role in Wnt/β-catenin pathway. Recently a lot of effort has been put into developing more potent and selective TNKS inhibitors and optimizing them towards anti-cancer agents. We noticed that some 2-phenylquinazolinones (2-PQs) reported as CDK9 inhibitors were similar to previously published TNKS inhibitors. In this study, we profiled this series of 2-PQs against TNKS and selected kinases that are involved in the Wnt/β-catenin pathway. We found that they were much more potent TNKS inhibitors than they were CDK9/kinase inhibitors. We evaluated the compound selectivity to tankyrases over the ARTD enzyme family and solved co-crystal structures of the compounds with TNKS2. Comparative structure-based studies of the catalytic domain of TNKS2 with selected CDK9 inhibitors and docking studies of the inhibitors with two kinases (CDK9 and Akt) revealed important structural features, which could explain the selectivity of the compounds towards either tankyrases or kinases. We also discovered a compound, which was able to inhibit tankyrases, CDK9 and Akt kinases with equal μM potency.
Kokoelmat
- Avoin saatavuus [37957]
